ZYDUS LIFESCIENCES LIMITED
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1952-01-01
- Employees
- -
- Market Cap
- $13.6B
- Website
- http://cadilapharma.com
Desidustat in the Treatment of Chemotherapy Induced Anemia
- Conditions
- Anemia of Chronic Kidney DiseaseChemotherapy Effect
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04667533
- Locations
- 🇮🇳
HCG Manavata Cancer Centre,, Nashik, Mahar Ashtra, India
Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)
- Conditions
- Covid19
- Interventions
- Drug: Pegylated Interferon-α2bOther: Standard of Care
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 7
- Registration Number
- NCT04480138
- Locations
- 🇲🇽
Avant Sante site 2, Zapopan, Jalisco, Mexico
🇲🇽Avant Sante Site 1, Monterrey, Mexico
Desidustat in the Management of COVID-19 Patients
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04463602
- Locations
- 🇲🇽
Avant Sante Site 1, Monterrey, Mexico
Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
- Conditions
- Chronic Kidney Disease Stage 5 on Dialysis
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 392
- Registration Number
- NCT04215120
- Locations
- 🇮🇳
Karnavati Hospital Pvt.Ltd, Ahmedabad, Gujarat, India
🇮🇳Shalby Hospital,, Ahmedabad, Gujarat, India
🇮🇳DHS Multispecialty Hospital, Ahmedabad, Gujarat, India
Desidustat in the Treatment of Anemia in CKD
- Conditions
- Chronic Kidney Disease Stage 3AnemiaChronic Kidney Disease Stage 4Chronic Kidney Disease Stage 5
- Interventions
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 588
- Registration Number
- NCT04012957
- Locations
- 🇮🇳
Sunrise Hospital, Vijayawada, Andhra Pradesh, India
🇮🇳Max Super Specialty Hospital, New Delhi, Delhi, India
🇮🇳Thakershey Charitable trust Hospital, Ahmadabad, Gujarat, India
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: ZYDPLA1 tabletDrug: Placebo tablet
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 84
- Registration Number
- NCT02620592
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States
To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 850
- Registration Number
- NCT02005666
- Locations
- 🇺🇸
Universal BioPharma Research, Dinuba, California, United States
🇺🇸Research Across America, Santa Ana, California, United States
🇺🇸Visions Clinical Research, Boynton Beach, Florida, United States
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 56
- Registration Number
- NCT01972893
- Locations
- 🇮🇳
Zydus Research Centre, Survey No. 396/403, Opp. Sarvotam Hotel, Nr. Nova Petrochemicals, Sarkhej-Bavla N.H. No. 8A, Village : Moraiya,, Ahmedabad, Gujarat, India
A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT01543269
- Locations
- 🇮🇳
Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad-, Gujarat, India
A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 109
- Registration Number
- NCT01539616
- Locations
- 🇮🇳
Vijayratna Diabetes Diagnosis & Treatment Centre, Upper Ground Floor, Sumeru Centre, Nr Parimal Underbridge, Paldi, Ahmedabad, Gujarat, India
🇮🇳Devi Hospital,Ground floor, Naranpura, Ahmedabad, Gujarat, India
🇮🇳Private clinic, 4, Stadium House, Ground Floor, Navrangpura, Ahmedabad, Gujarat, India